Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12029-018-0165-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preoperative intensity-modulated radiation therapy in lower extremity soft tissue sarcomas with and without dose avoidance of uninvolved skin/subcutaneous tissue.
Cancer
September 2025
Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.
Background: The objective of this study was to evaluate whether dosimetric sparing of uninvolved normal tissues, including skin/subcutaneous flaps, affects acute and late toxicities in preoperative image-guided intensity-modulated radiation therapy (IG-IMRT) for lower extremity soft tissue sarcomas (LE-STS).
Methods: Patients with LE-STS from a phase 2 preoperative IG-IMRT trial (flap-sparing-IMRT, 2005-2009) and a prospectively maintained institutional database (standard-IMRT, 2005-2020) were propensity matched by age, sex, tumor size, grade, location, wound closure, and interval from IG-IMRT to surgery; all received 50 Gy in 25 fractions preoperatively. The primary outcome was major wound complication (MWC).
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
Oncogene
September 2025
Department of Internal Medicine, Hematology/Oncology Division, University of Michigan Medical School, Ann Arbor, MI, USA.
Bladder cancer is a common malignancy whose lethality is determined by invasive potential. We have previously shown that TRIM29, also known as ATDC, is transcriptionally regulated by TP63 in basal bladder cancers where it promotes invasive progression and metastasis, but the molecular events which promote invasion and metastasis downstream of TRIM29 remained poorly understood. Here we identify stimulation of bladder cancer migration as the specific role of TRIM29 during invasion.
View Article and Find Full Text PDFIntegrating radiomics, artificial intelligence, and molecular signatures in bone and soft tissue tumors: advances in diagnosis and prognostication.
Front Oncol
August 2025
Department of Imaging, Yantaishan Hospital, Yantai, Shangdong, China.
This systematic review evaluates the integration of radiomics, artificial intelligence (AI), and molecular signatures for diagnosing and prognosticating bone and soft tissue tumors (BSTTs). Following PRISMA 2020 guidelines, we analyzed 24 studies from 1,141 initial records across PubMed, Scopus, Web of Science, and Google Scholar. Our findings reveal that while radiomics-AI pipelines are well-developed for BSTT assessment - particularly using MRI (72% of studies) and CT (25%) with machine learning classifiers like random forests (42%) and CNNs (17%) - molecular data integration remains virtually absent.
View Article and Find Full Text PDFGrade 2 central chondrosarcoma treated by intralesional curettage: observation or surgery? : a multicentre retrospective study.
Bone Joint J
September 2025
Department of Orthopaedics and Traumatology, University Medical Center Freiburg, Freiburg, Germany.
Aims: The most appropriate management of patients who have undergone curettage for a suspected low-grade chondrosarcoma (CS), which has subsequently been found to be of grade 2, remains unknown. We aimed to assess whether these patients have an increased risk of local recurrence and distant metastasis if followed up over time, compared to those who undergo further treatment soon after the diagnosis has been established.
Methods: A retrospective study was undertaken which included 71 patients treated between January 2010 and December 2022 by intralesional curettage for a supposed low-grade CS, but who subsequently proved to have a histological grade 2 CS.
The role of radiotherapy and chemotherapy in extraskeletal myxoid chondrosarcoma.
J Orthop Surg Res
August 2025
Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1- 1 Tsukiji, Chuoku, Tokyo, 104-0045, Japan.
Background: Extraskeletal myxoid chondrosarcoma (EMC) is an extremely rare subtype of sarcoma characterized by NR4A3 gene rearrangement. Despite being considered slowly progressive sarcomas, EMCs tend to have local recurrences and distant metastases in the late stages. This study aimed to investigate the prognostic factors of EMCs, especially the effect of (neo)adjuvant radiotherapy or chemotherapy on localized EMCs and chemotherapy on advanced-stage EMCs.
View Article and Find Full Text PDF